Immunotherapy

Top Research Topics at Immunotherapy?

The journal is organized to address concerns in the fields of Immunology, Immunotherapy, Internal medicine, Immune system and Oncology. The concepts on Immunology presented in it can also apply to other research fields, including Disease and Transplantation. Topics in Immunotherapy explored in Immunotherapy were investigated in conjunction with research in Tumor microenvironment and Cancer research.

Cancer research research presented in Immunotherapy encompasses a variety of subjects, including Cytotoxic T cell and Chimeric antigen receptor. Internal medicine and Gastroenterology are closely related fields of research discussed in Immunotherapy. The work tackled in Immunotherapy goes beyond the discipline of Immune system as it also encompasses Vaccination.

The journal focuses on Oncology but the discussions also offer insight into other areas such as Pembrolizumab and Melanoma. Non small cell is a key component of Lung cancer research discussed in the journal. The studies tackled, which mainly focus on Nivolumab, apply to Ipilimumab as well.

• Immunology (50.09%)
• Immunotherapy (43.84%)
• Internal medicine (28.31%)

What are the most cited papers published in the journal?

• Immunotherapeutic implications of IL-6 blockade for cytokine storm (329 citations)
• Toll-like receptor agonists in cancer therapy (202 citations)
• Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. (168 citations)

Research areas of the most cited articles at Immunotherapy:

The most cited papers are organized to reinforce research efforts on Immunology, Immunotherapy, Immune system, Cancer and Cancer research. While work presented in the journal publications provide substantial information on Immunology, it also covers topics in Internal medicine and Disease. While the primary focus in the journal publications is Immunotherapy, they also dissect topics surrounding Adoptive cell transfer and Chimeric antigen receptor as a whole.

What topics the last edition of the journal is best known for?

• Internal medicine
• Cancer
• Immune system

The previous edition focused in particular on these issues:

The main points discussed in the journal deals with Internal medicine, Immunotherapy, Oncology, Cancer and Pembrolizumab. Most of the Internal medicine studies addressed also intersect with Gastroenterology. The research on Immunotherapy tackled can also make contributions to studies in the areas of Cancer research, Melanoma and Disease.

Chemotherapy, Atezolizumab, Immune checkpoint inhibitors, Meta-analysis and PD-L1 are some topics wherein Oncology research discussed in it have an impact. Immune system studies covered in the journal falls within the purview of Immunology. It connects research in Immunology with the related topic of Cytokine storm.

The most cited articles from the last journal are:

• Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. (22 citations)
• Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. (17 citations)
• Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma. (8 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Immunotherapy (based on the number of publications) are:

• Hampig Raphael Kourie (15 papers) published 3 papers at the last edition, 2 more than at the previous edition,
• Melissa Bersanelli (12 papers) absent at the last edition,
• Soudeh Ghafouri-Fard (11 papers) absent at the last edition,
• Sebastiano Buti (11 papers) absent at the last edition,
• Lingdi Zhao (10 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Immunotherapy (based on the number of publications) are:

• French Institute of Health and Medical Research (29 papers) published 1 paper at the last edition,
• Saint Joseph's University (25 papers) published 9 papers at the last edition, 6 more than at the previous edition,
• Harvard University (25 papers) published 4 papers at the last edition, 3 more than at the previous edition,
• Mayo Clinic (22 papers) published 1 paper at the last edition, 1 less than at the previous edition,
• Zhengzhou University (22 papers) published 1 paper at the last edition, 2 less than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 12.86% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 19.67% were posted by at least one author from the top 10 institutions publishing in the journal. Another 4.10% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 10.66% of all publications and 65.57% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.